Sign In
Buy ADPT
$22.57
-1.61 (-6.66%)
At Close: Jul 31, 2026
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
04:05pm, Wednesday, 15'th Oct 2025
SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
10:40am, Friday, 26'th Sep 2025
Here is how Adaptive Biotechnologies (ADPT) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Adaptive Biotechnologies Corporation (ADPT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
03:58pm, Wednesday, 10'th Sep 2025
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Chad Robins - Co-Founder, CEO & Chairman
Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies (ADPT) is a Great Choice
01:01pm, Monday, 01'st Sep 2025
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
04:05pm, Wednesday, 27'th Aug 2025
SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
10:41am, Monday, 25'th Aug 2025
Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?
10:15am, Wednesday, 13'th Aug 2025
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?
10:41am, Friday, 08'th Aug 2025
Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Aristotle Focus Growth Q2 Highlights: Top Performers, Surprises And Strategic Shifts
06:05am, Friday, 08'th Aug 2025
Adaptive Biotechnologies and Netflix were top contributors, driven by strong earnings, momentum in core businesses, and positive outlooks. UnitedHealth Group and Visa detracted from performance due to
Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday
07:01pm, Wednesday, 06'th Aug 2025
Just after market close, Adaptive Biotechnologies (ADPT 5.97%) took the wraps off its second quarter. The following day, investors reacted to this by bidding the biotech company's stock up by almost 6
Adaptive (ADPT) Q2 Revenue Surges 36%
01:57pm, Wednesday, 06'th Aug 2025
Adaptive (ADPT) Q2 Revenue Surges 36%
Adaptive Biotechnologies Corporation (ADPT) Q2 2025 Earnings Call Transcript
02:13am, Wednesday, 06'th Aug 2025
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Chad M. Robins - Co-Founder, CEO & Chairman Karina Calzadilla - Vice
Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings
08:30pm, Tuesday, 05'th Aug 2025
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key m
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
07:01pm, Tuesday, 05'th Aug 2025
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.26 per share a year ago.
Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
04:05pm, Tuesday, 05'th Aug 2025
SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gen
